Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arctic Bioscience AS ( (DE:9TD) ) just unveiled an update.
Arctic Bioscience, a biotechnology company specialising in marine-based pharmaceuticals and dietary supplements, is developing the oral psoriasis drug candidate HRO350 while selling its ROMEGA-branded products and bulk ingredients worldwide. The company leverages a specialised team with diverse expertise to support both its drug development pipeline and global nutraceutical operations.
Arctic Bioscience has released its 2025 annual report, including the Board of Directors’ report and audited financial statements, following approval by the board on 6 May 2026. The publication provides investors and other stakeholders with updated insight into the company’s financial performance and governance, and fulfills the firm’s regulatory disclosure obligations under applicable securities laws.
More about Arctic Bioscience AS
Arctic Bioscience is a biotechnology company focused on developing and commercialising pharmaceutical products and dietary supplements derived from bioactive marine raw materials. The company is advancing HRO350, an oral drug candidate for mild-to-moderate psoriasis, and markets marine-based dietary supplements globally as bulk ingredients and under the ROMEGA brand.
Average Trading Volume: 16,881
Current Market Cap: NOK88.96M
For detailed information about 9TD stock, go to TipRanks’ Stock Analysis page.